NeuroNext biomarker study explores natural history of infantile-onset SMA

January 9, 2018, The Ohio State University

Research led by The Ohio State University Wexner Medical Center to define the natural history of infantile-onset spinal muscular atrophy (SMA) has been "critical" to accelerate the development of effective therapies and hasten their approval by the FDA," said principal investigator Dr. Stephen J. Kolb, director of the OSU ALS/Motor Neuron Disease Translational Research Program at Ohio State's Neurological Institute.

Findings of the study are published online in the journal Annals of Neurology.

"Clinical in this population require an understanding of disease progression and identification of meaningful biomarkers to hasten therapeutic development and predict outcomes," Kolb said. "This study has generated definitive controlled data on the natural history of infantile-onset SMA. With the advent of effective disease-modifying therapies, it's likely not ethical or feasible to perform future clinical trials that have a placebo arm in which sick children don't receive available treatment. Thus, our data sets are critical for future investigation of improved therapies."

SMA is an inherited condition that causes nerve cells in the lower part of the brain and spinal cord to break down and die. The infantile-onset form is the leading genetic cause of infant death, typically before age two.

The study assessed infant motor function scales and possible electrophysiological, protein and molecular biomarkers at baseline and subsequent visits for 27 healthy and 26 infants with the most severe form of SMA. A total of 23 healthy infants and seven SMA infants completed the study, and the median age of survival for infants with two copies of the SMN2 gene was eight months.

According to an accompanying editorial in the Annals of Neurology, this study is "already serving as the gold standard for the natural history of untreated infantile SMA."

"The control infant data obtained here is also novel, contributes to our understanding of postnatal neuromuscular development and provides a first benchmark to indicate full recovery in SMA trials and optimal clinical management," Kolb said. "Considerations for effective clinical trial design in infantile-onset SMA can be gleaned from this study and recent ."

The study was a prospective, multi-center, longitudinal study in SMA and healthy infants designed to mimic a clinical trial. The protocol, patient demographics and baseline characteristics were published previously.

Explore further: Researchers seek biomarker to assess spinal muscular atrophy treatment

More information: Stephen J. Kolb et al. Natural history of infantile-onset spinal muscular atrophy, Annals of Neurology (2017). DOI: 10.1002/ana.25101

Related Stories

Researchers seek biomarker to assess spinal muscular atrophy treatment

June 19, 2017
Spinal muscular atrophy (SMA) is the leading genetic cause of death in infants, affecting 1 in 11,000 live births. As promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical ...

Study finds new treatment for spinal muscular atrophy safe for infants

December 6, 2016
Infants as young as five weeks old with the most severe form of spinal muscular atrophy (SMA) - a leading genetic cause of infant mortality - can be treated safely with nusinersen. This investigational treatment slowed progression ...

New study focuses on treatment for epilepsy caused by tuberous sclerosis

May 8, 2017
A clinical trial of a drug that researchers hope can prevent or delay the onset of epilepsy in children with tuberous sclerosis has begun at McGovern Medical School at The University of Texas Health Science Center at Houston ...

Phase 1 study shows encouraging data for gene replacement therapy for SMA type I

November 1, 2017
A one-time intravenous infusion of the high dose of gene therapy extended the survival of patients with spinal muscular atrophy type 1 (SMA1) in a Phase 1 clinical trial, according to a study published today in the New England ...

Drug study first effort to prevent onset of epilepsy in tuberous sclerosis complex

October 18, 2016
Researchers at the University of Alabama at Birmingham have launched the first drug study aimed at preventing or delaying the onset of epilepsy in children with a genetic condition known as tuberous sclerosis complex. UAB ...

L. reuteri DSM17938 effective for colic in breastfed infants

December 27, 2017
(HealthDay)—Lactobacillus reuteri DSM17938 is effective for breastfed infants with colic, according to a meta-analysis published online Dec. 26 in Pediatrics.

Recommended for you

Inflammation in the womb may explain why some babies are more prone to sepsis after birth

October 9, 2018
Each year 15 million infants are born preterm and face high risks of short- and long-term complications, including sepsis, severe inflammation of the gut, and neurodevelopmental disorders. A new report in the American Journal ...

Dummies not to blame for common speech disorder in kids

October 9, 2018
New University of Sydney research shows bottles, dummies, and thumb sucking in the early years of life do not cause or worsen phonological impairment, the most common type of speech disorder in children.

'Genes are not destiny' when it comes to weight

October 9, 2018
A healthy home environment could help offset children's genetic susceptibilities to obesity, according to new research led by UCL.

Old drug could have new use helping sick premature babies

October 8, 2018
Researchers from The University of Western Australia, King Edward Memorial Hospital and Curtin University are investigating whether an old drug could be used to help very sick premature babies.

Insufficient sleep associated with risky behavior in teens

October 1, 2018
Adolescents require 8-10 hours of sleep at night for optimal health, according to sleep experts, yet more than 70 percent of high school students get less than that. Previous studies have demonstrated that insufficient sleep ...

Checked off 'the talk' with your teen? Not so fast: Once isn't enough

October 1, 2018
Patting yourself on the back for gritting through "the talk" with your kid? Not so fast: new research from Brigham Young University family life professor Laura Padilla-Walker suggests that when it comes to your teens, one ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.